September 25, 2007 - Cure Lab, Inc. submits a provisional patent application on technology that allows for the increase in efficiency of vaccination with recombinant vaccines.
It is known that the naturally occurring codons of genes encoding for an antigen and/or therapeutic protein may be suboptimal. Together with computational biologists from The Technical University of Munich, Cure Lab has developed a technology that enables the codon optimization of these genes, thereby enhancing their immunogenicity.
|
